(PharmaNewsWire.Com, June 11, 2020 ) This market is expected to reach USD 13.28 Billion by 2021 from USD 7.45 Billion in 2016, at a CAGR of 12.3%. A number of factors such as the improved approval rate for therapeutic antibodies by regulatory authorities, patent expiry of blockbuster monoclonal antibodies, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies are key drivers for the growth of the antibody production market.
Moreover, the increasing risk of infectious diseases and rising demand for protein therapeutics are expected to drive market growth during the forecast period.
The antibody production market comprises several players such as GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Pall Corporation (U.S.), Sigma-Aldrich Corporation (Germany), Eppendorf AG (Germany), Cellab GmbH (Germany), INTEGRA Biosciences AG (Switzerland), and FiberCell Systems Inc. (U.S.).
New product launches; expansions; agreements, alliances, collaborations, and partnerships; mergers and acquisitions; and others (new service launches, product enhancements, and spin-offs) are the major strategies followed by players to achieve growth in this market. New product launches accounted for ~51% of the total developments undertaken by the players in this market. The key players that adopted this strategy are Eppendorf AG (Germany), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Agilent Technologies, Inc. (U.S.).
Market expansions accounted for ~17% of the total developments adopted by market players from January 2013 to May 2016. Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Repligen Corporation (U.S.), Novasep Holding S.A.S. (France), and Merck KGaA (Germany) were the key players that carried out these developments. Players adopted this strategy to strengthen their networks, increase their global presence, enhance customer experience, and improve relationships with customers. For instance, in March 2016, Sartorius Stedim Biotech (Germany) opened a new subsidiary with sales office in Lima (Peru) with an aim to expand the company’s pharmaceutical market.
Agreements, alliances, partnerships, and collaborations accounted for ~15% of the total developments adopted by players in the antibody production market between January 2013 and May 2016. This strategy was employed by companies to strengthen their market positions and enhance the availability of their products to a wider population base. The key players that adopted this strategy include GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), and Parker Hannifin Corporation (U.S.).
Mergers and acquisitions accounted for ~11% of the total strategic developments undertaken by players operating in the antibody production market between 2013 and 2016. Players adopted this strategy to leverage the expertise of the acquired companies, in order to enhance their antibody production portfolios. The key players that adopted this strategy include Sartorius AG (Germany), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), Applikon Biotechnology (Netherlands), and Merck KGaA (Germany).
Other developments such as new service launches, product enhancements, and spin-offs accounted for 3% of the total strategic developments. The companies that adopted these strategies include GE Healthcare (U.S.), Cellexus Limited (U.K.), Sartorius AG (Germany), and Cellab GmbH, (Germany).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
